secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001193125-23-055156
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences expands TYRA-300 into achondroplasia with positive preclinical data; TYRA-200 IND cleared
--------------------------------------------------------------------------------

- TYRA-300 increased body length by 17.6% in FGFR3 Y367C/+ mice (p<0.0001); femur +24.4%, tibia +38.3%, L4-L6 +23.9%.
- Company plans to submit IND for Phase 2 study in pediatric achondroplasia in 2024.
- FDA cleared IND for TYRA-200, an FGFR1/2/3 inhibitor; first patient dosing expected H2 2023.
- Compensation Committee adopted annual incentive plan; CEO target bonus 50% of base salary, other execs 40%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312523055156/0001193125-23-055156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312523055156/d446194d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-055156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer